90Y-FAPI-46诊疗一体化使3例孤立性纤维性肿瘤患者达到近完全代谢缓解
本文报道3例转移性孤立性纤维性肿瘤(SFT)患者,在标准治疗耗尽后经分子分型显示成纤维细胞活化蛋白α(FAPα)高表达,依据分子肿瘤委员会建议接受90Y-FAPI-46放射性药物治疗,获得代谢消退与症状缓解,且仅见轻微不良事件。
要点
- 3例转移性SFT患者经FAPα分子筛查后接受90Y-FAPI-46放射性药物治疗。
- 治疗后出现代谢消退与症状缓解,疾病控制经RECIST和PERCIST确认。
- 治疗耐受良好,仅观察到轻微不良事件。
核心结论
- 研究结果强调FAPα筛查作为预测性生物标志物的效用,以及FAP靶向放射性药物治疗作为晚期SFT可行治疗手段的潜力。
研究设计与样本
- 3例转移性SFT患者在标准治疗耗尽后接受分子分型,显示FAPα表达升高。
- 对参与分子辅助分层用于肿瘤根除研究计划(多中心观察性研究)的3例患者活检样本检测FAPα的信使RNA与蛋白表达。
- 信使RNA表达水平以每百万转录本量化,RNA提取、测序与数据处理采用既定方案。
- 蛋白表达采用重组抗FAPα抗体经FAPα免疫组化评估与染色。
- 依据分子肿瘤委员会建议,因68Ga-FAPI-46 PET/CT扫描观察到高摄取,这些患者接受90Y标记成纤维细胞活化蛋白抑制剂(FAPI)-46放射性药物治疗。
主要发现
- 90Y-FAPI-46放射性药物治疗带来实质性临床获益,包括代谢消退与症状缓解。
- 疾病控制经RECIST和PERCIST确认。
- 治疗耐受良好,仅观察到轻微不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Solitary fibrous tumor (SFT) is a rare soft-tissue sarcoma with limited treatment options, especially in advanced or metastatic cases. Fibroblast activation protein α (FAPα) is overexpressed in certain sarcomas, including SFTs, making it a promising target for diagnostics and radiopharmaceutical therapy (RPT). We present the cases of 3 patients with metastatic SFTs who, after exhausting standard treatments, underwent molecular profiling and showed elevated FAPα expression. Methods: Messenger RNA and protein expression of FAPα were examined in biopsy samples from 3 patients participating in the Molecularly Aided Stratification for Tumor Eradication Research program, a multicenter observational study focused on biology-driven stratification of adults with advanced cancer. Messenger RNA expression levels were quantified as transcripts per million, with RNA extraction, sequencing, and data processing performed using established protocols. Protein expression was assessed and stained with FAPα immunohistochemistry using a recombinant anti-FAPα antibody. Following the recommendation of the molecular tumor board, these patients received 90Y-labeled fibroblast activation protein inhibitor (FAPI)-46 RPT because of the high uptake observed in 68Ga-FAPI-46 PET/CT scans. Results: 90Y-FAPI-46 RPT led to substantial clinical benefits, including metabolic resolution and symptom relief, with disease control confirmed using RECIST and PERCIST. Treatment was well-tolerated, with only minor adverse events observed. Conclusion: Our findings underscore the utility of FAPα screening as a predictive biomarker and the potential of FAP-targeted RPT as a viable treatment for advanced SFT.
引用
- Lanzafame H, Heilig CE, Wardelmann E, et al. 90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors. J Nucl Med. 2025. PMID: 40707141. doi:10.2967/jnumed.125.269572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。